Objective To explore the effects of linagliptin combined with metforminon glucolipid metabolism and pancreatic islet β cell function indicators in the treatment of patients with type 2 diabetes mellitus (T2DM) complicated with dyslipidemia. Methods 153 patients with T2DM and dyslipidemia admitted to the hospital from May 2020 to October 2022 were selected as observation subjects, and were divided into observation group (76 cases) and control group (77 cases) by the simple randomization method. The control group was treated with metformin, and the observation group was additionally given linagliptin on this basis. The blood glucose indicators ［fasting plasma glucose (FPG), 2h postprandial blood glucose (2hPBG)］, blood lipids ［total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C)］ and pancreatic islet cell function indicators ［fasting insulin, insulin-like growth factor 1 (IGF-1), insulin auto-antibody (IAA)］ were compared between the two groups before treatment and after 5 months of treatment. Results After 5 months of treatment, theFPG, 2hPBG, TC, TG and LDL-Cin both groups were significantly decreased, and the above indicators in observation group were lower than those in control group. The levels of HDL-C, fasting insulin and IGF-1were significantly increased in both groups after 1 months of treatment, and the levels in observation group were higher than those in control group. Conclusion Linagliptin combined with metformin has a significant clinical efficacy, and it can effectively improve the glucolipid metabolism in patients with T2DM complicated with dyslipidemia, and it is beneficial to the recovery of patients